- Predictive
Oncology subsidiary TumorGenesis developing new PDx models needed to
understand the complexities of cancer
- Tremendous
unmet need for patient-derived tumors (PDx) for new drug development –
current mouse models unreliable
- TumorGenesis
unique in the industry; its ovarian-cancer cells haven’t been widely
available like most other PDx samples
- Multi-billion-dollar
market opportunity
As the precision-medicine industry continues to integrate
technology to improve the efficiency and efficacy of its strategies, clinicians
are realizing the need for actual patient samples to determine the best methods
to defeat cancer. Researchers are now turning to patient-derived tumors (PDx)
to better understand the complexities and vagaries of the disease which has
become the new focus in cancer research. Predictive
Oncology Inc. (NASDAQ: POAI) is executing on its mission to deliver
cutting-edge services for the oncology research and profiling market. The
company’s subsidiary, TumorGenesis, was formed in 2018 with a mission to create
reliable, reproducible and translatable cancer cell capture, culture and
screening using lab-ready to use technologies.
TumorGenesis will build kits used in cancer research
laboratories around the world. Kits, media and cells are valued today at $2.8
billion growing at CAGR 12.9% to $6.8 billion by 2025.Predictive Oncology
believes TumorGenesis’ novel PDx platform will provide pharmaceutical and
biotech companies the tools needed to identify, understand and attack tumors.
Through the work of TumorGenesis on PDx profiles, Predictive Oncology intends
to become an important conduit for rapid drug identification, development and
approvals – objectives worth billions in the space.
PDx models have proved to be a critical component of early
cancer detection and the global research community has focused efforts on
mastering the complexities of cancer and moving rapidly to PDx models to do so.
There’s now a major emphasis in cancer research to learn more about cancer’s
origins and find ways to identify early that cancer is present and then prevent
or treat cancer cells and cancer cell colonies in their infancy, long before
overt symptoms of cancer reveal themselves. Certain cancers like ovarian,
pancreatic and brain cancers as well as many others, are highly metastatic,
have little if any treatment options and little reliable way of early
detection.
However, to study cancer cells, they must be isolated and
perpetuated: in short, immortalized. Unfortunately, this process created more
aberrations of the genetics of the isolated cancer cells. The isolation or
“immortalization” of these cancer cell lines also created what researchers call
homogeneous cancer colonies, meaning the cancer cells all behaved the same way.
Tumors are not homogeneous but are heterogeneous and other
researchers have found that the homogeneous cell lines are also admixed with
clonal variants that can rapidly mutate even further, confounding research.
Tumors and cancer cells are much more complex than originally perceived.
Everyone in the cancer research community has now focused
efforts on mastering the culturing of cancer cells and preserving their in vivo
(in patient) characteristics. The goal is to successfully grow in the
laboratory and subsequently implanted in mice or rats (PDx Mouse and PDx Rat),
a tumor that accurately represents the patient’s tumor. TumorGenesis is rapidly
developing its technology in this multibillion-dollar industry of Patient
Derived Tumors (PDx), the focus of all pharmaceutical, biotech, government and
independent research institutes around the world.
TumorGenesis currently has 25 ovarian-cancer cell types that
have been validated utilizing PDx samples. The company’s program includes plans
to isolate these ovarian-cancer cell types and study their response to drugs,
which is unique in the industry as these ovarian-cancer cells haven’t been
widely available like almost all other PDx samples. This gives POAI, via
TumorGenesis, a striking competitive advantage which can be measured both
qualitatively and quantitatively. Using its unique PDx samples then screening
drugs and drug combinations against its extensive library of ovarian-cancer
cell types, TumorGenesis is building the kits that are desperately needed
facilitate the development of new, more effective drugs that are created in
response real human cancer cells. Through its utilization of PDx models,
TumorGenesis’ work has synergistically supported Predictive Oncology’s quest to
deliver the necessary tools to defeat ovarian cancer first then move to all
other cancer sub-types. This is Predictive Oncology’s overarching strategy,
delineated in its CancerQuest2020 initiative.
Predictive Oncology is a data and AI-driven discovery
services company that provides predictive models of tumor drug response to
improve clinical outcomes for patients. POAI is at the vanguard of the latest
scientific endeavors in cancer research: to better understand the complexities
of individual cancers and tailor individualized therapeutic protocols. In
addition to providing the molecular information necessary to help deliver on
the promise of personalized medicine, the comprehensive molecular information
delivered by Predictive Oncology is of enormous value to Pharma in new drug
development and the PDx models developed by TumorGenesis may provide the
pathways for Pharma to find successful solutions to the scourge of cancer.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
